KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Operating Income (2017 - 2026)

Amneal Pharmaceuticals has reported Operating Income over the past 9 years, most recently at $112.0 million for Q4 2025.

  • For Q4 2025, Operating Income rose 47.81% year-over-year to $112.0 million; the TTM value through Dec 2025 reached $394.1 million, up 58.06%, while the annual FY2025 figure was $394.1 million, 58.06% up from the prior year.
  • Operating Income for Q4 2025 was $112.0 million at Amneal Pharmaceuticals, up from $70.3 million in the prior quarter.
  • Over five years, Operating Income peaked at $138.1 million in Q4 2022 and troughed at -$198.6 million in Q2 2022.
  • A 5-year average of $50.4 million and a median of $68.7 million in 2021 define the central range for Operating Income.
  • On a YoY basis, Operating Income climbed as much as 1135.44% in 2022 and fell as far as 395.92% in 2022.
  • Year by year, Operating Income stood at $11.2 million in 2021, then skyrocketed by 1135.44% to $138.1 million in 2022, then plummeted by 89.72% to $14.2 million in 2023, then soared by 434.02% to $75.8 million in 2024, then soared by 47.81% to $112.0 million in 2025.
  • Business Quant data shows Operating Income for AMRX at $112.0 million in Q4 2025, $70.3 million in Q3 2025, and $111.4 million in Q2 2025.